Serum Hepcidin quantification in differentiation of anemia

×

Error message

User warning: The following theme is missing from the file system: journalijdr. For information about how to fix this, see the documentation page. in _drupal_trigger_error_with_delayed_logging() (line 1138 of /home2/journalijdr/public_html/includes/bootstrap.inc).

International Journal of Development Research

Serum Hepcidin quantification in differentiation of anemia

Abstract: 

Hepcidin is a 25-amino peptide hormone that regulates iron homeostasis. Its serum quantification helps to provide the right therapeutic choice in iron-deficiency anemia and anemia in chronic diseases. We determined serum hepcidin levels using ELISA assay in 125 patients with chronic kidney diseases (CKD) [stages from II to V] (n=60), rheumatoid arthritis (n=30), β-talasemia major (n=15) and iron-deficiency anemia (IDA; n=20) for a period 2012 – 2014 year. We compare their results to control group. The reference ranges for serum hepcidin in Bulgarian population are 3.052 - 37.750 µg/L. We found statistically significant differences in serum hepcidin levels between measured groups: CKD stages II to IV – 89.9 ± 9.2 μg/L; CKD stage V – 321.4 ± 20.5 μg/L; β-talasemia major – 0.78 ± 0.9 μg/L; ; IDA – 1.14 ± 1.2 μg/L; RA – 27.9 ± 8.7 μg/L; P < 0.001. Our results may support the right choice of a therapeutic approach to the anemia in patients with different disorders of iron homeostasis.

Download PDF: